SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : OSI Pharmaceuticals (OSIP) - formerly Oncogene
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: scaram(o)uche who wrote (230)9/20/2004 11:29:39 AM
From: scaram(o)uche  Read Replies (1) of 447
 
Dr. Colin Goddard:

There's an outstanding question, that absolutely fascinates me.

A biotech would usually crow about a partnered program, where the partner was about to transition to a phase II human clinical trial addressing a huge market.

So...... as SLV320 was advancing at Solvay, why did you suddenly go silent about the adenosine receptor program in general, and re. SLV320 in particular? I'm not implying that there's anything sinister. But it just seems particularly weird. What am I missing? You went silent "pre-angio, pre-IMCL, etc." at a point where the stock needed goosing, so it's not like you'd have forgotten about a chunk of CHF.

Thanks, in advance, for any answer. Your 10-K filings have been insufficient.

Richard Harmon
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News